الفهرس | Only 14 pages are availabe for public view |
Abstract Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin’s lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge . The treatment of patients with relapsed or refractory disease remains challenging. the standard of care is high-dose chemotherapy followed by stem cell transplant. adirect comparison of conventional chemotherapy versus high-dose chemotherapy with SCT in the treatment of patients with relapsed NHL demonstrated that nearly half of the patients who received the high-dose treatment survived five years or more without cancer compared to 10% of the patients treated with conventional chemotherapy. This prospective randomised study compared the efficacy and toxicity of gemcitabene / carboplatine /dexa versus ESHAP protocol as second line salvage chemotherapy regimen in treatment of relapsed and refractory aggressive non-Hodgkin’s lymphoma (NHL).. In our study as regards the efficacy There was no statistically significant difference in response rate and time to disease progression between the two arms. as regards the hematological toxicity there was no statistical significant differences between both groups but in non hematological toxicity the renal toxicity was increased in ESHAP arm, it was reported in 5 cases compared to 1 case only in Gem/Carbo/dexa arm. |